المؤلفون: Mojca, Jensterle, Manfredi, Rizzo, Martin, Haluzík, Andrej, Janež

المساهمون: Jensterle, Mojca, Rizzo, Manfredi, Haluzík, Martin, Janež, Andrej

مصطلحات موضوعية: Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Weight Loss, Glucagon-Like Peptides, Diabetes, GLP-1 RAs, Liraglutide, Obesity, Semaglutide, Humans, Hypoglycemic Agents, Pharmacology (medical), Obesity, General Medicine, Liraglutide, Weight Gain, Glucagon-Like Peptide-1 Receptor

الوصف: The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for chronic weight management provides a novel effective strategy against obesity. The reliable models that might predict weight reducing potential at the individual level have not been identified yet. However, the coexistence of diabetes has been consistently related with less effective response than in people without this comorbidity. We aimed to review the efficacy of GLP-1 RAs approved for weight management in individuals with and without diabetes and discuss some potential mechanisms for consistently observed differences in efficacy between these two populations. The mean weight loss difference between GLP-1 RAs and placebo as add-on to lifestyle intervention in patients with diabetes was 4% to 6.2% compared to 6.1 to 17.4% in people without diabetes. Semaglutide compared to liraglutide resulted in greater weight loss. Some hypothetical explanations for the weaker anti-obesity response for both GLP-1 RAs in people with diabetes include the background medications that promote weight gain, the fear of hypoglycaemia inherently related to the treatment of diabetes, a decrease in glycosuria and subsequently less weight loss in diabetics, an altered microbiota in patients with obesity and diabetes and a genetic background that predispose to weight gain in patients with diabetes. Moreover, people with diabetes may have had obesity for longer and may be less adherent to exercise, which seems to potentiate the effects of GLP-1 RA. Emerging multimodal approaches combining peptides targeting receptors at different levels might therefore be of additional benefit particularly in patients with diabetes.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2cd738c2e382889801d3387b0191cf0Test
https://hdl.handle.net/10447/584531Test

المؤلفون: Deborah J. Wexler, Chantal Mathieu, Peter Rossing, Judith E. Fradkin, Geltrude Mingrone, Apostolos Tsapas, David A. D'Alessio, Walter N. Kernan, John B. Buse, Melanie J. Davies

المصدر: Diabetes Care

مصطلحات موضوعية: 0301 basic medicine, Glucose-lowering therapy, Endocrinology, Diabetes and Metabolism, Disease, Type 2 diabetes, 030204 cardiovascular system & hematology, chemistry.chemical_compound, 0302 clinical medicine, Chronic kidney disease, Weight management, CARDIOVASCULAR RISK-FACTORS, Insulin, MULTIPLE DAILY INJECTIONS, RANDOMIZED CONTROLLED-TRIAL, Cardiovascular disease, Lifestyle management, 3. Good health, Europe, Cardiovascular Diseases, CLINICAL-PRACTICE GUIDELINES, Life Sciences & Biomedicine, Type 2, Adult, medicine.medical_specialty, Consensus, Consensus Report, 030209 endocrinology & metabolism, Heart failure, Patient-centred care, Guidelines, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, Lixisenatide, Endocrinology & Metabolism, Internal medicine, Diabetes mellitus, Weight Loss, Type 2 diabetes mellitus, Diabetes Mellitus, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Obesity, COTRANSPORTER 2 INHIBITORS, Renal Insufficiency, Chronic, Intensive care medicine, Life Style, Sodium-Glucose Transporter 2 Inhibitors, INTENSIVE MEDICAL THERAPY, Advanced and Specialized Nursing, Science & Technology, business.industry, Semaglutide, Settore MED/09 - MEDICINA INTERNA, Type 2 Diabetes Mellitus, Liraglutide, medicine.disease, United States, Costs, GLARGINE PLUS LIXISENATIDE, FIXED-RATIO COMBINATION, 030104 developmental biology, chemistry, Diabetes Mellitus, Type 2, Hyperglycemia, PEPTIDE-1 RECEPTOR AGONISTS, business, Hypoglycaemia, Mace, Kidney disease, DIPEPTIDYL PEPTIDASE-4 INHIBITORS

الوصف: The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min-1 [1.73 m]-2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

وصف الملف: Print

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a5e07d878a99a4bdc6a4d6c6f273125Test
https://lirias.kuleuven.be/handle/123456789/633989Test